Olfactory Outcomes After Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyposis Authors: Elysia Grose, Jenny B Xiao, Patrick Macinnis, Yvonne Chan, John M Lee Published: 2026 ABSTRACT ABSTRACTObjectiveTo evaluate subjective and objective olfactory outcomes in patients undergoing endoscopic sinus surgery (ESS) for chronic rhinosinusitis with nasal polyps (CRSwNP).MethodsProspective, single‐center study including adult patients undergoing ESS for CRSwNP from July 2022 to May 2024. Olfactory status was assessed using the Sinonasal Outcome Test (SNOT‐22) and Sniffin' Sticks odor identification test preoperatively and at 1‐, 3‐, and 6‐months postoperatively.ResultsThirty‐six patients (45% female, mean age: 48 ± 14) were included. Among them, 47% had asthma, 53% had a history of previous sinus surgery, and 28% had aspirin‐exacerbated respiratory disease. Mean SNOT‐22 score decreased from 57 ± 20 to 22 ± 18, 15 ± 14, and 25 ± 19, at 1‐, 3‐, and 6‐months postoperatively, respectively (p < 0.001). Mean Sniffin' Sticks identification test score improved from 5.2 ± 4.4 odors identified (out of 16) to 7.9 ± 3.9, 8.3 ± 4.7, and 7.7 ± 4.9 points at 1‐, 3‐, and 6‐months postoperatively, respectively, with statistically significant improvements at 1‐ and 3‐months (p < 0.001) and at 6‐months (p = 0.012).ConclusionThis prospective study demonstrates improvements in subjective and objective measures of olfaction after ESS in patients with CRSwNP. While the sense of smell may be the most difficult symptom to address with surgical intervention, our study provides direct evidence that appropriate surgical intervention can in fact provide meaningful improvements to a large proportion of patients with nasal polyps. Longer‐term studies will be required to determine if these improvements will remain sustained.Level of Evidence3.Keywords: chronic rhinosinusitis, endoscopic sinus surgery, olfaction Introduction Chronic rhinosinusitis with nasal polyposis (CRSwNP), characterized by inflammation of the paranasal sinuses, is strongly linked to olfactory dysfunction and results in significant decreases in olfactory‐specific quality of life (QOL) [1, 2, 3, 4]. In cases of medically‐refractory CRSwNP, endoscopic sinus surgery (ESS) has been shown to improve disease‐specific QOL; however, the impact of ESS on olfactory dysfunction is less well‐established. Recent studies have reported variable rates of olfactory improvement after ESS ranging from 25% to 100%, with others reporting no change or worsening of olfaction [5, 6, 7, 8]. These inconsistencies in the literature may in part be due to the fact that many of these studies employ subjective measures of olfaction and there is a lack of standardization in the measurement of olfactory dysfunction. Furthermore, there are few prospective studies evaluating how objective measures of olfaction change over time after ESS. Recently, biologic therapy has emerged as a new option for the treatment of uncontrolled CRSwNP. The existing literature has demonstrated that biologic therapy, particularly dupilumab, has produced rapid and sustained improvements in objective and subjective measures of olfaction in CRSwNP [9, 10]. However, biologic therapies have significant financial costs and are not without their adverse effects including dermatitis, conjunctivitis [11], alopecia areata, and arthritis [12, 13]. Particularly, in the resource constrained health care system, recent literature has focused on the comparative benefits and costs of ESS compared to biologics and found ESS to be more cost effective for upfront therapy [14, 15]. These new treatment options and their promising impact on olfactory dysfunction served as the impetus for a better understanding of how ESS alone impacts olfaction so that patients may be properly counseled regarding expected outcomes post‐surgery. There is no gold standard for the measurement of olfaction. However, the Sniffin' Sticks test is one of the most widely used and validated measurements of olfaction in the literature [16]. The Sniffin Stick's identification test consists of typically 12 or 16 pen‐like dispensing devices which have different odors. When compared to other olfactory tests, like the University of Pennsylvania Smell Identification Test (UPSIT), the Sniffin' Sticks identification test is more efficient, less costly, and there are some reports in the literature that may have slightly better sensitivity and specificity [17, 18]. Given the heterogeneity of the available data and the importance of olfactory outcomes in CRSwNP management, the present study aims to evaluate both subjective and objective olfactory outcomes in patients undergoing ESS for CRSwNP. Methods Enrollment Adult patients (≥ 18 years) with CRSwNP were enrolled from rhinology clinics at St. Michael's Hospital in Toronto, Canada in a prospective, longitudinal fashion from July 1, 2022 to August 1, 2024. Each patient was diagnosed according to the American and Canadian practice guidelines for CRSwNP [2, 3, 19]. Patients were enrolled irrespective of baseline olfactory function. Patients were excluded if they had missing preoperative olfactory function data, allergic fungal sinusitis, received a diagnosis of cystic fibrosis, primary ciliary dyskinesia, or immune deficiency, or were on biologic therapy at any time during the study. All patients underwent ESS with a full house ESS concept, whereby all affected sinuses were widely opened. Extended sinus procedures including the modified Lothrop and partial middle turbinate resection were performed at the discretion of the senior surgeon. Partial middle turbinate resection was performed only if the middle turbinate was grossly involved with disease. All patients were prescribed antibiotics, nasal saline irrigations and topical nasal steroids post‐surgery (either intranasal spray or in steroid irrigation). A short course of postoperative oral steroids was used at the surgeon's discretion, in patients with high polyp burden. The study was approved by the University of Toronto Research Ethics Boards (REB 18‐132), and all subjects were consented using a standardized consent form (Supporting Information 1). Patient drop‐out was defined as missed follow‐up visit, non‐compliance with study procedures, or expressed wish to withdraw from the study. Patients were included in the analysis if they completed at minimum 1‐month follow‐up. Patient Demographics Baseline, preoperative data were collected on the following patient demographics, including age, sex, and comorbidities such as asthma, ASA sensitivity, smoking history, and previous sinus surgery. The presence of medical comorbidities was based on patient self‐report of a prior physician diagnosis. Olfactory Outcome Measurements Quantitative olfactory screening was conducted using the identification subtest of the Sniffin' Sticks test (Burghardt, Wedel, Germany) [20] preoperatively and at 1‐, 3‐, and 6‐month postoperative follow‐up. The identification test involved 16 odorants presented at suprathreshold intensity, and subjects selected the correct odorant using a multiple‐choice format. All assessments were administered by the same clinical research coordinator, who was blinded to other study responses. Participants were given one point when they identified an odor correctly and got 0 points when they did not. The total Sniffin' Sticks identification test score was scored out of 16. The minimum clinically important difference (MCID) for the identification test was 3 [18]. The Sniffin' Sticks test provides a cutoff point of total scores (combined threshold, discrimination, and identification tests) to differentiate normosmia from hyposmia, with slight differences among age groups. According to the updated version of normative data provided by Oleszkiewicz et al., subjects from various age groups scored 10.99–13.63 out of 16 in an identification test [21]. Assessment of Health‐Related QOL The disease‐specific, health‐related QOL was evaluated by the validated SNOT‐22 questionnaire in patients with CRSwNP (Supporting Information 2) [22] preoperatively and at 1‐, 3‐, and 6‐month postoperative follow‐up. Each item ranged in score from zero to five (the higher the score, the worse the QOL), for a total score range of 0 to 110. The minimum clinically important difference for the SNOT‐22 score is 9.0 [23]. The olfactory‐specific question from the SNOT‐22, which asks patients about decreased sense of smell/taste (referred to hereafter as the SNOT‐22 smell score), was assessed independently. This specific item on the SNOT‐22 test asked patients to rate from a scale of 0 to 5 how severe they find the problem of “decreased sense of smell/taste” has been in the last 2 weeks, with 0 being not a problem and 5 being the “problem is as bad as it can be.” Statistical Analyses Data were analyzed using SPSS version 21.0 (SPSS Inc., Chicago, Illinois). Descriptive statistics were used to describe patient, disease, and treatment outcomes. Values are expressed as mean ± standard deviation (SD). Continuous data were tested for statistical significance using paired two‐tailed Student's t‐tests. A p value of < 0.05 was considered statistically significant. To account for drop‐out at 6‐months, a complete case analysis was used where significance at 6 months was calculated based only on those patients who completed all time points. Results Baseline Characteristics A total of 36 patients with CRSwNP were enrolled; 36 patients completed 1‐ and 3‐month follow up and 31 patients completed the full 6‐month follow up. Baseline characteristics of the full cohort are presented in Table 1. The mean age of the cohort was 48 ± 14 years, with just under half (42%) being female. Asthma, ASA sensitivity, and septal deviation were present in 47%, 28%, and 39% of the cohort, respectively. Approximately half of the cohort (n = 19/36, 53%) had at least one prior sinus surgery. The overall mean preoperative SNOT‐22, SNOT‐22 smell, and Sniffin' Stick identification scores of the cohort were 57 ± 20, 4.3 ± 1.0, and 5.2 ± 4.4 odors, respectively. TABLE 1Baseline patient characteristics.Preoperative1 month3 months6 months N 36363631Age, mean (SD)48 (14)48 (14)48 (14)50 (14)Female (%)15 (42)15 (42)15 (42)11 (35)ComorbiditiesAsthma (%)17 (47)17 (47)17 (47)14 (45)ASA sensitivity (%)10 (28)10 (28)10 (28)7 (23)Septal deviation (%)14 (39)14 (39)14 (39)13 (42)Smoking history, yes (%)6 (17)6 (17)6 (17)5 (16)Prior sinus surgery (%)19 (53)19 (53)19 (53)14 (45)NPS, right, mean (SD)2.4 (1.0), n = 29NDNDNDNPS, left, mean (SD)2.8 (0.95), n = 29NDNDNDLMK score, mean (SD)18 (4.4), n = 7NDNDNDPreop nasal saline rinse, yes (%)13 (36)13 (36)13 (36)11 (35)Preop nasal steroid spray, yes (%)14 (39)14 (39)14 (39)11 (35)Preop OCS, yes (%)12 (33)12 (33)12 (33)9 (29)SNOT‐22 score, mean (SD)57 (20)22 (18)15 (14)25 (19)SNOT‐22, smell score, mean (SD)4.3 (1.0)2.1 (1.8)1.9 (2.0)2.0 (1.9)Sniffin's sticks score, mean (SD)5.2 (4.4)7.9 (3.9)8.3 (4.7)7.7 (4.9)Abbreviations: ASA, acetylsalicylic acid; LMK, Lund–Mckay; ND, not documented; NPS, nasal polyp score; OCS, oral corticosteroids; SD, standard deviation. Baseline patient characteristics. Abbreviations: ASA, acetylsalicylic acid; LMK, Lund–Mckay; ND, not documented; NPS, nasal polyp score; OCS, oral corticosteroids; SD, standard deviation. Subjective Olfactory Outcomes Subjective olfactory outcomes, as assessed by the total SNOT‐22 and SNOT‐22 smell scores, showed significant improvement at all postoperative follow‐up time points (Figures 1 and 2). For SNOT‐22, the mean score decreased significantly from 57 ± 20 to 22 ± 18 (p < 0.001) and 15 ± 14 (p < 0.001) at 1‐ and 3‐month postoperative follow‐up, respectively. At 6‐months, mean SNOT‐22 scores increased to 25 ± 19; however, they were still significantly lower (p < 0.001) when compared to the baseline preoperative score (59 ± 19, n = 31). Mean SNOT‐22 smell score decreased significantly from 4.3 ± 1.0 to 2.1 ± 1.8 (p < 0.001) and 1.9 ± 2.0 (p < 0.001) at 1‐ and 3‐month postoperative follow‐up, respectively. At 6‐months, mean SNOT‐22 smell score decreased from 4.2 ± 1.1 to 2.0 ± 1.9 (p < 0.001, n = 31). Postoperative changes in total SNOT‐22 score. Postoperative changes in SNOT‐22 smell score. Objective Olfactory Outcomes Objective olfactory outcomes, measured using the Sniffin' Sticks identification test, similarly showed a trend to improvement at all postoperative follow‐up (Figure 3). Mean Sniffin' Sticks identification test score increased from 5.2 ± 4.4 to 7.9 ± 3.9 (p < 0.001) and 8.3 ± 4.7 (p < 0.001) at 1‐ and 3‐month postoperative follow‐up, respectively. At 6‐months, mean Sniffin' Sticks score decreased slightly to 7.7 ± 4.9, but remained significantly elevated from baseline score of 5.5 ± 4.1 (p = 0.013, n = 31). In the subset of patients who had AERD, Sniffin' Sticks identification scores improved significantly from baseline at 1 month postoperatively (2.9 ± 2.0 vs. 6.4 ± 4.7, p = 0.019) and 3 months postoperatively (2.8 ± 2.0 vs. 6.1 ± 3.4, p = 0.010). At 6 months postoperatively, this did not reach statistical significance (2.71 ± 1.70 vs. 5.71 ± 5.85, p = 0.220). Postoperative changes in Sniffin' Sticks identification test scores. Furthermore, the percentage of patients showing any improvement in their Sniffin' Sticks identification test score was 72% at 1‐month postoperative follow‐up, increasing to 75% at 3 months, and decreasing to 58% at 6 months (Figure 4). The percentage of patients who achieved a clinically significant improvement of at least 3 points in the Sniffin' Sticks identification test score was 61%, 50%, and 45% at 1‐, 3‐, and 6‐month postoperative follow‐up, respectively. Percentage of patients who improved in Sniffin' Sticks identification test scores postoperatively. For 1‐ and 3‐month, percentage calculations were based on a total of n = 36 patients. For 6‐month, percentage calculations were based on a total of n = 31 patients. Primary and Revision ESS on Olfactory Outcomes In patients undergoing primary surgery (no prior sinus surgery) (n = 17), mean SNOT‐22 scores at 1‐ and 3‐month follow up were not significantly different from patients who underwent revision surgery (at least one prior sinus surgery) (19 ± 18, 18 ± 22 for primary surgery and 25 ± 16 and 16 ± 13 for revision surgery; p = 0.301 and p = 0.823, respectively). SNOT‐22 scores at 6‐month follow up (n = 13) were also not significantly different between primary surgery and revision surgery patients (18 ± 13 and 27 ± 23; p = 0.220). SNOT‐22 smell score was significantly improved at 1‐ and 6‐month follow up in patients who underwent primary surgery compared to revision surgery (1.5 ± 1.6 and 1.2 ± 1.4 versus 2.8 ± 1.7 and 2.7 ± 2.1; p = 0.032 and p = 0.045). Similarly, Sniffin' Sticks identification test scores improved significantly at 1‐ and 3‐month follow up in patients who underwent primary surgery compared to revision surgery (10 ± 3.4, 10 ± 3.0, for primary surgery versus 6.0 ± 3.9 and 6.9 ± 4.3 for revision surgery; p = 0.026 and p = 0.015, respectively). At the 6‐month follow‐up, Sniffin' scores were still greater in the primary surgery group compared to the revision cohort although this did not reach statistical significance (9.7 ± 5.1 vs. 6.1 ± 4.9; p = 0.077). Discussion Olfactory dysfunction occurs in 48% to 83% of patients with CRSwNP and has a negative impact on patients' QOL [4, 24]. ESS is a primary core treatment modality for CRSwNP and may be the only treatment option for patients with refractory CRSwNP who are not candidates for biologic therapy. In theory, ESS not only removes obstructive polyps that impede olfactory function, but it can help reduce the inflammatory burden to help restore function of the olfactory neuro‐epithelium. However, the literature has reported variability in both the subjective and objective improvements in olfaction after ESS [7]. Thus, the purpose of this study was to conduct a prospective study to clarify the objective and subjective olfactory outcomes after ESS alone. This study evaluated subjective changes in olfaction and disease‐related QOL with the SNOT‐22 score. The overall SNOT‐22 score in our study decreased significantly at 1‐, 3‐, and 6‐months, which reiterates the positive impact ESS has in this patient population. Consistent with the current literature, this study demonstrated sustained improvements at 1‐, 3‐, and 6‐months postoperatively, with SNOT‐22 smell scores decreasing from above 4 out of 5 to approximately 2 out of 5 at each postoperative time point. Interestingly, other studies have demonstrated no significant difference in subjective olfactory outcomes when comparing ESS and dupilumab therapy up to 6‐months [22]. When evaluating objective measures of olfaction using the Sniffin' Sticks identification test, this study reinforced the improvements found in olfaction at each postoperative time interval. While the difference was statistically significant, increasing from a score of approximately 5 to above 7 at 1‐, 3‐, and 6‐months, the MCID for the Sniffin Sticks identification test is 3. Although this may suggest that the improvements are not clinically significant, our SNOT‐22 data would be contrary to this interpretation as patients continued to report clinically meaningful changes to their sense of smell subjectively. However, perhaps this underscores the fact that objective measures in smell provide a more granular assessment when compared to subjective outcomes. When looking at the data more closely, approximately half of the patients in this study increased their Sniffin' sticks identification scores above the MCID at 3‐months (50%) and 6‐months (45%) postoperatively. The existing literature is in keeping with the results of this study showing that olfaction seems to improve in the immediate postoperative period and then worsens progressively with time [25, 26]. In a recent study comparing dupilumab and ESS in CRSwNP they found that the change in the Sniffin' Sticks identification test favored dupilumab as early as 1‐month after treatment [25]. This is in keeping with other studies demonstrating marked improvement in the Sniffin' Sticks identification scores from 1.6 at Day 0 to 6.3 after 1 month and 9.0 at 4 months [27]. While one of the main purported benefits of dupilumab is improvement in olfaction, our findings suggest that surgery alone still provides a significant opportunity for meaningful improvement in smell. These results may suggest that the pathophysiology underlying olfactory dysfunction in CRSwNP may not be related to the volume of polyps but may depend more heavily on inflammatory processes in the olfactory epithelium [28]. When comparing olfactory outcomes in patients undergoing primary surgery versus revision surgery, this study showed that patients undergoing primary surgery had significantly greater improvements in SNOT‐22 smell scores at 1‐ and 6‐month follow up and in the Sniffin' Sticks identification test scores at 1‐ and 3‐month follow up. These findings align with previous literature suggesting that revision ESS tends to yield more modest olfactory improvements, likely due to cumulative mucosal damage, scarring, and altered sinonasal anatomy from prior surgeries. One prospective study evaluating patients undergoing revision ESS found a statistically significant improvement in UPSIT scores; however, these gains were generally smaller than those seen in patients undergoing primary ESS [29]. Furthermore, predictive factors for olfactory improvement include preoperative olfactory status, degree of polyp burden, and control of inflammation [30] and those with higher disease burden and more significant inflammation are at higher risk of revision ESS [31, 32]. This study has some notable limitations. First, cultural differences and inadequate translation may limit patient performance on the Sniffin' Sticks identification test [33]. Variability in surgical technique, extent of surgery, presenting disease burden, and postoperative treatment protocols including frequency and duration of steroid usage are also potential confounding variables that can affect smell outcomes. In the present study, the surgical approach was relatively standardized across patients and followed full‐house FESS principles, allowing for a more focused evaluation of olfactory outcomes after ESS alone. When the middle turbinate was severely polypoid or lateralized, a subset of patients underwent partial inferior middle turbinate resection to preserve the superior olfactory fibers. Given the lack of strong evidence suggesting that limited partial middle turbinate resection adversely affects olfaction, this variation was unlikely to meaningfully confound olfactory outcomes [34]. Moreover, given the small sample size, the authors were not able to control for comorbidities such as asthma and aspirin sensitivity which are known to worsen olfactory dysfunction [35]. Furthermore, reasoning for patient drop‐out at 6‐months was not fully elucidated and if not at random, has the potential to introduce bias in smell outcomes at 6‐months. Additionally, this study did not account for the impact that preoperative olfaction can have on postoperative outcomes. Future larger prospective studies should evaluate whether baseline olfactory severity can predict olfactory recovery after surgery. Conclusion In conclusion, despite inconsistencies in the literature regarding the efficacy of ESS in improving olfactory function, our prospective study provides direct real‐world evidence that both subjective and objective measures of smell can improve following surgical intervention. This is important for patient counseling, especially as we navigate treatment options in the era of biologics. Further research is necessary to elucidate additional factors that influence long‐term outcomes. Funding The authors have nothing to report. Ethics Statement The Research Ethics Board at Unity Health Toronto approved this study. Conflicts of Interest J.M.L. is a speaker and on the advisory board for Sanofi Regeneron and GlaxoSmithKline. The other authors declare no conflicts of interest. Supporting information Supporting Information: 1. Consent form. Supporting Information: 2. Sinonasal Outcome Test‐22 Questionnaire. Acknowledgments The authors have nothing to report. Grose E., Xiao J. B., Macinnis P., Chan Y., and Lee J. M., “Olfactory Outcomes After Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyposis,” Laryngoscope Investigative Otolaryngology 11, no. 3 (2026): e70473, 10.1002/lio2.70473. This paper was presented as an oral presentation at the 2024 American Academy of Otolaryngology—Head and Neck Surgery Meeting; September 28 to October 1, 2024; Miami, Florida, USA. Data Availability Statement The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. References Associated Data Supplementary Materials Supporting Information: 1. Consent form. Supporting Information: 2. Sinonasal Outcome Test‐22 Questionnaire. Data Availability Statement The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.